Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free ASMB Stock Alerts

Assembly Biosciences (ASMB) Financials

Assembly Biosciences logo
$25.91 +0.36 (+1.41%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$25.90 0.00 (-0.02%)
As of 07/27/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Assembly Biosciences

Annual Income Statements for Assembly Biosciences

This table shows Assembly Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -28 -44 -43 -91 -98 -203 -130 -93 -61 -40 -6.12
Consolidated Net Income / (Loss)		 -28 -44 -43 -91 -98 -62 -130 -93 -61 -40 -6.12
Net Income / (Loss) Continuing Operations		 -28 -44 -43 -91 -98 -203 -130 -93 -61 -40 -6.12
Total Pre-Tax Income 		-28 -45 -52 -90 -98 -62 -132 -93 -61 -40 -6.12
Total Operating Income		 -30 -45 -52 -93 -103 -65 -133 -94 -65 -45 -12
Total Gross Profit		 0.00 0.00 9.02 15 16 79 6.25 0.00 7.16 29 72
Total Revenue		 0.00 0.00 9.02 15 16 79 6.25 0.00 7.16 29 72
Operating Revenue		 0.00 0.00 9.02 15 16 79 6.25 0.00 7.16 29 72
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 30 45 61 108 119 288 139 94 72 74 84
Selling, General & Admin Expense		 11 12 17 35 33 37 29 24 23 18 20
Research & Development Expense		 18 33 44 73 86 107 69 70 49 56 65
Total Other Income / (Expense), net		 1.20 0.40 0.37 3.08 4.31 5.25 0.30 1.02 3.45 5.57 6.00
Interest & Investment Income		 1.20 1.54 0.98 3.08 4.31 2.62 0.30 1.02 3.45 5.57 6.00
Income Tax Expense		 0.00 -0.62 -9.05 1.10 -0.77 0.00 -2.53 0.00 0.03 0.33 0.00
Basic Earnings per Share		 ($1.81) ($2.57) ($2.41) ($3.98) ($3.72) ($1.75) ($3.00) ($23.08) ($13.38) ($6.69) ($0.55)
Weighted Average Basic Shares Outstanding		 15.70M 17.23M 17.75M 22.80M 26.26M 35.43M 43.28M 4.03M 4.58M 6.00M 11.21M
Diluted Earnings per Share		 ($1.81) ($2.57) ($2.41) ($3.98) ($3.72) ($1.75) ($3.00) ($23.08) ($13.38) ($6.69) ($0.55)
Weighted Average Diluted Shares Outstanding		 15.70M 17.23M 17.75M 22.80M 26.26M 35.43M 43.28M 4.03M 4.58M 6.00M 11.21M
Weighted Average Basic & Diluted Shares Outstanding		 15.70M 17.23M 17.75M 22.80M 26.26M 35.43M 43.28M 51.95M 5.48M 7.50M 15.86M

Quarterly Income Statements for Assembly Biosciences

This table shows Assembly Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Consolidated Net Income / (Loss)		 -14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Net Income / (Loss) Continuing Operations		 -14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Total Pre-Tax Income 		-14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Total Operating Income		 -15 -13 -11 -12 -11 -12 -9.94 -11 -11 20 -11
Total Gross Profit		 0.00 7.16 5.79 8.53 6.85 7.36 9.42 9.63 11 42 8.21
Total Revenue		 0.00 7.16 5.79 8.53 6.85 7.36 9.42 9.63 11 42 8.21
Operating Revenue		 0.00 7.16 5.79 8.53 6.85 7.36 9.42 9.63 11 42 8.21
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 15 20 17 21 18 19 19 21 22 23 20
Selling, General & Admin Expense		 4.22 8.71 4.64 4.48 4.29 4.61 4.51 4.59 5.09 5.42 4.68
Research & Development Expense		 11 11 12 16 14 14 15 16 17 17 15
Total Other Income / (Expense), net		 0.63 1.62 1.65 1.46 1.34 1.12 1.12 0.90 1.69 2.29 2.29
Interest & Investment Income		 0.63 1.62 1.65 1.46 1.34 1.12 1.12 0.90 1.69 2.29 2.29
Basic Earnings per Share		 ($3.29) ($2.39) ($1.66) ($1.98) ($1.51) ($1.72) ($1.17) ($1.33) ($0.72) $1.97 ($0.54)
Weighted Average Basic Shares Outstanding		 4.38M 4.58M 5.48M 5.64M 6.35M 6.00M 7.51M 7.66M 12.69M 11.21M 16.90M
Diluted Earnings per Share		 ($3.29) ($2.39) ($1.66) ($1.98) ($1.51) ($1.72) ($1.17) ($1.33) ($0.72) $1.97 ($0.54)
Weighted Average Diluted Shares Outstanding		 4.38M 4.58M 5.48M 5.64M 6.35M 6.00M 7.51M 7.66M 12.69M 11.21M 16.90M
Weighted Average Basic & Diluted Shares Outstanding		 65.71M 5.48M 5.51M 6.35M 6.36M 7.50M 7.64M 7.67M 15.82M 15.86M 15.89M

Annual Cash Flow Statements for Assembly Biosciences

This table details how cash moves in and out of Assembly Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.98 1.47 53 -41 5.26 13 -14 6.79 -33 19 20
Net Cash From Operating Activities		 -19 -35 1.86 -65 -84 -63 -93 -84 23 -51 -41
Net Cash From Continuing Operating Activities		 -19 -35 1.86 -65 -84 -63 -93 -84 23 -51 -41
Net Income / (Loss) Continuing Operations		 -28 -44 -43 -91 -98 -62 -130 -93 -61 -40 -6.12
Consolidated Net Income / (Loss)		 -28 -44 -43 -91 -98 -62 -130 -93 -61 -40 -6.12
Depreciation Expense		 0.06 0.08 0.22 0.64 0.49 0.69 0.47 0.50 0.45 0.13 0.13
Amortization Expense		 - 0.00 0.00 -0.23 -1.74 -0.01 0.59 0.16 - -3.66 -2.35
Non-Cash Adjustments To Reconcile Net Income		 7.82 6.16 8.97 32 26 24 48 9.82 1.17 5.93 5.64
Changes in Operating Assets and Liabilities, net		 1.87 3.14 35 -6.23 -12 -25 -13 -1.84 82 -13 -38
Net Cash From Investing Activities		 -65 36 -16 -135 -50 68 27 91 -69 40 -113
Net Cash From Continuing Investing Activities		 -65 36 -16 -135 -50 68 27 91 -69 40 -113
Purchase of Property, Plant & Equipment		 -0.06 -0.15 -0.87 -0.34 -1.55 -0.47 -3.10 -0.10 -0.26 -0.03 -0.07
Purchase of Investments		 -70 -7.95 -48 -184 -281 -193 -160 -28 -134 -91 -230
Sale and/or Maturity of Investments		 4.98 44 33 49 233 263 188 117 65 131 116
Net Cash From Financing Activities		 82 0.15 67 160 140 7.60 53 0.61 14 29 175
Net Cash From Continuing Financing Activities		 82 0.15 67 160 140 7.60 53 0.61 14 29 175
Issuance of Common Equity		 82 0.15 65 156 135 6.13 53 0.61 14 29 169
Other Financing Activities, net		 - - 2.39 3.96 4.24 1.47 - - 0.00 0.01 5.64

Quarterly Cash Flow Statements for Assembly Biosciences

This table details how cash moves in and out of Assembly Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 5.03 -6.82 -1.09 0.46 9.24 9.89 -15 0.59 -1.47 36 -27
Net Cash From Operating Activities		 -14 74 -18 -17 -15 -0.41 -23 -17 -15 14 -22
Net Cash From Continuing Operating Activities		 -14 74 -18 -17 -15 -0.41 -23 -17 -15 14 -22
Net Income / (Loss) Continuing Operations		 -14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Consolidated Net Income / (Loss)		 -14 -11 -9.08 -11 -9.61 -10 -8.82 -10 -9.20 22 -9.08
Depreciation Expense		 0.12 0.08 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Amortization Expense		 -0.31 - -1.26 -0.96 -0.84 -0.59 -0.51 -0.38 - - -0.79
Non-Cash Adjustments To Reconcile Net Income		 1.53 -4.01 2.27 1.66 0.20 1.79 0.76 0.64 1.17 3.07 0.47
Changes in Operating Assets and Liabilities, net		 -0.76 88 -10 -6.68 -5.03 8.70 -15 -6.85 -8.03 -8.60 -13
Net Cash From Investing Activities		 19 -90 17 5.11 24 -6.70 6.59 17 -158 21 -5.38
Net Cash From Continuing Investing Activities		 19 -90 17 5.11 24 -6.70 6.59 17 -158 21 -5.38
Purchase of Property, Plant & Equipment		 -0.14 -0.07 -0.01 -0.01 - - 0.00 - -0.04 -0.02 -0.02
Purchase of Investments		 -2.65 -108 -3.71 -31 -15 -41 -20 -18 -181 -12 -63
Sale and/or Maturity of Investments		 22 19 21 36 39 34 26 35 23 33 58
Net Cash From Financing Activities		 - 9.19 0.00 12 - 17 1.92 0.36 172 0.46 0.15
Net Cash From Continuing Financing Activities		 - 9.19 0.00 12 - 17 1.92 0.36 172 0.46 0.15
Issuance of Common Equity		 - 9.19 0.00 12 - 17 1.92 0.36 166 0.37 0.00
Other Financing Activities, net		 - - 0.00 0.00 - 0.00 0.00 - 5.55 0.09 0.15

Annual Balance Sheets for Assembly Biosciences

This table presents Assembly Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 134 98 169 268 340 283 191 102 137 119 258
Total Current Assets		 68 54 123 223 283 224 154 97 134 116 255
Cash & Equivalents		 27 29 82 41 47 59 46 52 20 38 58
Short-Term Investments		 41 24 38 177 227 157 101 39 110 74 190
Accounts Receivable		 - 0.00 2.27 2.43 3.37 1.23 0.34 0.94 0.04 0.00 0.97
Prepaid Expenses		 0.70 0.61 0.90 1.99 5.36 6.85 7.24 4.41 3.50 3.42 5.47
Plant, Property, & Equipment, net		 0.15 0.21 0.86 0.56 1.83 1.60 1.14 0.74 0.39 0.28 0.22
Total Noncurrent Assets		 65 44 45 45 55 57 36 4.08 2.65 3.38 2.82
Long-Term Investments		 23 2.44 3.35 - - 0.00 28 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 0.20 0.26 0.34 3.35 14 16 7.75 4.08 2.65 3.38 2.82
Total Liabilities & Shareholders' Equity		 134 98 169 268 340 283 191 102 137 119 258
Total Liabilities		 15 18 56 57 67 43 22 19 96 86 51
Total Current Liabilities		 3.40 7.12 13 18 24 24 16 16 39 48 49
Accounts Payable		 1.36 2.37 2.12 3.69 1.73 4.60 2.66 2.49 0.46 0.59 1.17
Accrued Expenses		 2.04 4.75 6.14 9.68 13 16 10 10 6.63 9.14 10
Current Deferred Revenue		 - 0.00 5.23 5.10 6.41 - - 0.00 31 38 37
Other Current Liabilities		 - - - 0.00 3.19 3.40 3.15 3.36 1.22 0.46 0.57
Total Noncurrent Liabilities		 12 11 43 39 42 18 6.06 2.83 57 38 2.06
Other Noncurrent Operating Liabilities		 - - - 0.00 9.08 6.73 3.33 0.10 1.12 2.63 2.06
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 119 80 113 211 273 241 169 83 41 33 207
Total Preferred & Common Equity		 119 80 113 211 273 241 169 83 41 33 207
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 119 80 113 211 273 241 169 83 41 33 207
Common Stock		 284 289 365 553 713 742 801 808 827 859 1,039
Retained Earnings		 -164 -208 -251 -342 -439 -502 -631 -725 -786 -826 -832
Accumulated Other Comprehensive Income / (Loss)		 -0.82 -0.60 -0.39 -0.35 -0.20 -0.27 -0.42 -0.80 -0.08 -0.21 -0.04

Quarterly Balance Sheets for Assembly Biosciences

This table presents Assembly Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 52 120 115 100 99 81 240 236
Total Current Assets		 50 117 113 98 96 77 237 233
Cash & Equivalents		 27 19 19 28 23 24 23 31
Short-Term Investments		 20 94 90 67 68 51 210 195
Accounts Receivable		 0.00 0.04 0.00 0.00 0.00 0.00 0.91 0.45
Prepaid Expenses		 3.46 4.15 3.71 3.26 4.50 2.49 3.34 5.56
Plant, Property, & Equipment, net		 0.56 0.37 0.35 0.32 0.25 0.22 0.23 0.21
Total Noncurrent Assets		 1.40 2.35 2.04 1.73 3.24 3.09 2.96 2.68
Long-Term Investments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 1.40 2.35 2.04 1.73 3.24 3.09 2.96 2.68
Total Liabilities & Shareholders' Equity		 52 120 115 100 99 81 240 236
Total Liabilities		 9.92 87 81 74 72 63 57 37
Total Current Liabilities		 7.13 39 41 42 47 47 53 35
Accounts Payable		 0.76 0.73 0.80 1.34 0.88 0.74 1.68 1.13
Accrued Expenses		 5.51 4.11 6.12 6.35 4.41 5.10 8.79 4.20
Current Deferred Revenue		 - 33 33 33 41 41 42 29
Other Current Liabilities		 0.87 1.15 1.30 1.33 0.53 0.53 0.55 0.59
Total Noncurrent Liabilities		 2.78 49 39 33 25 15 3.92 1.90
Other Noncurrent Operating Liabilities		 0.05 0.79 0.45 0.11 2.49 2.35 2.21 1.90
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 42 33 35 26 27 18 183 199
Total Preferred & Common Equity		 42 33 35 26 27 18 183 199
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 42 33 35 26 27 18 183 199
Common Stock		 817 828 841 842 862 863 1,037 1,040
Retained Earnings		 -775 -795 -806 -816 -835 -845 -854 -841
Accumulated Other Comprehensive Income / (Loss)		 -0.28 -0.24 -0.29 -0.16 -0.25 -0.28 -0.09 -0.37

Annual Metrics And Ratios for Assembly Biosciences

This table displays calculated financial ratios and metrics derived from Assembly Biosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 17,225,662.00 17,225,554.00 17,397,731.00 25,463,172.00 26,047,046.00 33,022,336.00 47,861,677.00 48,779,985.00 65,709,112.00 6,356,286.00 15,817,140.00
DEI Adjusted Shares Outstanding		 1,435,472.00 1,435,463.00 1,449,811.00 2,121,931.00 2,170,587.00 2,751,861.00 3,988,473.00 4,064,999.00 5,475,759.00 6,356,286.00 15,817,140.00
DEI Earnings Per Adjusted Shares Outstanding		 -19.82 -30.83 -29.53 -42.77 -44.98 -73.94 -32.56 -22.90 -11.18 -6.32 -0.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 64.14% 7.83% 395.55% -92.09% -100.00% 0.00% 298.16% 153.52%
EBITDA Growth		 -23.58% -56.60% -13.56% -75.44% -12.60% 40.86% -114.13% 29.00% 31.31% 23.75% 70.71%
EBIT Growth		 -23.79% -56.52% -13.84% -75.49% -10.76% 39.49% -113.49% 29.07% 31.31% 29.74% 73.32%
NOPAT Growth		 -23.79% -52.68% -15.35% -77.56% -10.76% 36.94% -104.84% 29.07% 31.31% 29.74% 73.32%
Net Income Growth		 -19.61% -55.55% 3.28% -111.99% -7.58% 36.34% -108.93% 28.31% 34.23% 34.38% 84.76%
EPS Growth		 46.76% -41.99% 6.23% -65.15% 6.53% 52.96% -71.43% 28.31% 34.23% 50.00% 91.78%
Operating Cash Flow Growth		 -24.87% -86.56% 105.33% -3,592.37% -29.42% 25.11% -48.35% 9.56% 126.93% -324.76% 19.61%
Free Cash Flow Firm Growth		 61.15% -50.22% 93.31% -3,449.66% -16.02% 10.40% 10.36% 0.70% 155.83% -220.81% -8.58%
Invested Capital Growth		 -6.09% -11.58% -141.56% 27.00% 88.88% 3,025.54% -123.46% -57.78% -896.53% 11.70% 47.47%
Revenue Q/Q Growth		 0.00% 0.00% 58.14% 2.91% 6.91% -4.50% -14.22% 0.00% 0.00% 0.68% 94.41%
EBITDA Q/Q Growth		 -6.79% -11.62% -1.85% -17.65% -2.15% -14.61% -21.53% 29.79% 14.63% -5.82% 66.91%
EBIT Q/Q Growth		 -6.81% -11.62% -1.98% -17.84% -2.35% -15.49% -21.24% 29.78% 13.89% 2.19% 72.11%
NOPAT Q/Q Growth		 -6.81% -8.88% -0.80% -17.84% -2.35% -20.36% -21.24% 29.78% 13.89% 2.19% 72.11%
Net Income Q/Q Growth		 -5.64% -9.39% 16.63% -34.25% -0.95% -24.76% -19.12% 28.91% 15.73% 1.54% 84.12%
EPS Q/Q Growth		 -15.29% -9.36% 18.86% -29.22% 0.53% -6.06% 35.62% 28.91% 15.73% -4.21% 81.91%
Operating Cash Flow Q/Q Growth		 -11.06% -19.06% 214.95% -11.99% -4.74% -8.14% 5.95% 0.13% 132.42% -322.86% 26.27%
Free Cash Flow Firm Q/Q Growth		 -2.05% -17.76% -125.76% 4.36% -5.65% 0.56% 19.75% -18.10% 164.37% -232.17% 7.38%
Invested Capital Q/Q Growth		 -2.58% 4.17% 49.56% -64.79% -84.38% -25.89% -116.40% -43.20% -1,882.87% -14.17% 17.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -583.47% -623.62% -651.22% -77.71% -2,104.83% 0.00% -896.22% -171.63% -19.83%
Operating Margin		 0.00% 0.00% -579.08% -626.42% -643.44% -81.89% -2,121.65% 0.00% -902.50% -159.26% -16.76%
EBIT Margin		 0.00% 0.00% -585.90% -626.42% -643.44% -78.57% -2,121.65% 0.00% -902.50% -159.26% -16.76%
Profit (Net Income) Margin		 0.00% 0.00% -474.65% -613.02% -611.63% -78.57% -2,076.35% 0.00% -854.78% -140.87% -8.47%
Tax Burden Percent		 100.00% 98.62% 82.55% 101.23% 99.21% 100.00% 98.09% 100.00% 100.05% 100.83% 100.00%
Interest Burden Percent		 95.95% 96.68% 98.14% 96.68% 95.81% 100.00% 99.77% 98.91% 94.66% 87.73% 50.52%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -511.14% 0.00% 0.00% -388.56% -1,004.40% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -504.15% 0.00% 0.00% -381.71% -985.49% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 466.78% 0.00% 0.00% 364.37% 940.98% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.09% -44.57% -44.36% -56.06% -40.36% -24.19% -63.42% -74.00% -98.95% -107.92% -5.10%
Cash Return on Invested Capital (CROIC)		 -66.35% -109.22% 0.00% 0.00% 0.00% -291.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -39.52% -42.41% -33.79% -19.95% -55.95% 0.00% -54.18% -35.49% -6.43%
Return on Assets (ROA)		 0.00% 0.00% -32.02% -41.50% -32.12% -19.95% -54.75% 0.00% -51.32% -31.39% -3.25%
Return on Common Equity (ROCE)		 -32.09% -44.57% -44.36% -56.06% -40.36% -24.19% -63.42% -74.00% -98.95% -107.92% -5.10%
Return on Equity Simple (ROE_SIMPLE)		 -23.96% -55.41% -37.84% -43.08% -35.74% -25.83% -76.87% -112.61% -148.98% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -32 -37 -65 -72 -45 -93 -66 -45 -32 -8.48
NOPAT Margin		 0.00% 0.00% -405.35% -438.49% -450.41% -57.32% -1,485.16% 0.00% -631.75% -111.48% -11.73%
Net Nonoperating Expense Percent (NNEP)		 -12.81% -17.16% -7.00% -15.14% -10.46% -6.85% -18.91% -20.44% -14.40% -6.92% 1.31%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -110.11% -95.31% -4.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 188.72% 235.06% 206.22% 46.85% 460.19% 0.00% 319.82% 63.14% 27.12%
R&D to Revenue		 0.00% 0.00% 490.35% 491.36% 537.22% 135.04% 1,095.68% 0.00% 682.67% 196.12% 89.64%
Operating Expenses to Revenue		 0.00% 0.00% 679.08% 726.42% 743.44% 363.77% 2,221.65% 0.00% 1,002.50% 259.26% 116.76%
Earnings before Interest and Taxes (EBIT)		 -30 -46 -53 -93 -103 -62 -133 -94 -65 -45 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -46 -53 -92 -104 -61 -132 -93 -64 -49 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.09 2.62 6.96 2.73 1.95 0.83 0.66 0.77 1.31 3.01 2.60
Price to Tangible Book Value (P/TBV)		 1.68 5.47 11.01 3.41 2.30 1.00 0.66 0.77 1.31 3.01 2.60
Price to Revenue (P/Rev)		 0.00 0.00 87.29 38.91 33.38 2.53 17.83 0.00 7.52 3.52 7.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.38 6.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 73.62 24.18 16.22 0.00 0.00 0.00 0.00 0.00 4.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 356.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.68 -0.74 -0.93 -1.05 -1.02 -0.95 -0.95 -1.06 -1.79 -3.25 -1.50
Leverage Ratio		 1.16 1.17 1.39 1.35 1.26 1.21 1.16 1.16 1.93 3.44 1.57
Compound Leverage Factor		 1.11 1.13 1.36 1.31 1.20 1.21 1.16 1.15 1.83 3.02 0.79
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.31 2.92 6.13 4.06 2.95 0.73 -2.99 -10.08 -8.38 -9.34 2.91
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 20.09 7.52 9.13 12.05 11.57 9.19 9.59 5.95 3.41 2.42 5.22
Quick Ratio		 19.88 7.44 9.06 11.94 11.35 8.91 9.14 5.68 3.32 2.34 5.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -28 -1.91 -68 -79 -70 -63 -63 35 -42 -46
Operating Cash Flow to CapEx		 -32,175.21% -23,729.25% 215.03% -19,105.29% -5,409.72% -13,395.11% -4,171.33% -82,806.86% 9,845.45% -182,560.71% -62,262.12%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.07 0.07 0.05 0.25 0.03 0.00 0.06 0.22 0.38
Accounts Receivable Turnover		 0.00 0.00 0.00 6.29 5.50 34.36 7.99 0.00 14.51 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 16.78 20.89 13.37 46.13 4.57 0.00 12.70 85.26 286.35
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 57.99 66.36 10.62 45.70 0.00 25.15 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 57.99 66.36 10.62 45.70 0.00 25.15 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 28 24 -10 -7.43 -0.83 24 -5.67 -8.95 -89 -79 -41
Invested Capital Turnover		 0.00 0.00 1.26 -1.68 -3.87 6.78 0.68 0.00 -0.15 -0.34 -1.20
Increase / (Decrease) in Invested Capital		 -1.79 -3.21 -35 2.75 6.60 25 -30 -3.28 -80 10 37
Enterprise Value (EV)		 38 154 664 358 259 -17 -63 -28 -76 -12 290
Market Capitalization		 129 209 787 576 533 200 112 63 54 100 538
Book Value per Share		 $6.89 $4.64 $6.50 $8.27 $10.49 $7.29 $3.53 $1.69 $0.63 $5.25 $13.07
Tangible Book Value per Share		 $4.48 $2.22 $4.11 $6.64 $8.89 $6.02 $3.53 $1.69 $0.63 $5.25 $13.07
Total Capital		 119 80 113 211 273 241 169 83 41 33 207
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -91 -55 -123 -218 -274 -216 -175 -92 -130 -112 -248
Capital Expenditures (CapEx)		 0.06 0.15 0.87 0.34 1.55 0.47 2.24 0.10 0.23 0.03 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.70 -6.51 -10 -14 -16 -16 -8.50 -11 -36 -44 -42
Debt-free Net Working Capital (DFNWC)		 65 46 110 204 258 200 138 81 95 68 206
Net Working Capital (NWC)		 65 46 110 204 258 200 138 81 95 68 206
Net Nonoperating Expense (NNE)		 7.69 13 6.25 26 26 17 37 27 16 8.38 -2.36
Net Nonoperating Obligations (NNO)		 -91 -55 -123 -218 -274 -216 -175 -92 -130 -112 -248
Total Depreciation and Amortization (D&A)		 0.06 0.08 0.22 0.41 -1.24 0.68 1.05 0.65 0.45 -3.53 -2.22
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -114.43% -94.91% -98.37% -20.67% -135.85% 0.00% -498.19% -155.61% -58.56%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,215.51% 1,378.21% 1,618.37% 252.90% 2,208.68% 0.00% 1,320.15% 237.38% 284.59%
Net Working Capital to Revenue		 0.00% 0.00% 1,215.51% 1,378.21% 1,618.37% 252.90% 2,208.68% 0.00% 1,320.15% 237.38% 284.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($21.72) ($30.84) ($28.92) ($47.76) ($44.64) ($21.00) ($36.00) ($23.04) ($13.38) ($6.69) ($0.55)
Adjusted Weighted Average Basic Shares Outstanding		 1.44M 1.44M 1.69M 2.13M 2.72M 3.19M 4.01M 4.03M 4.58M 6.00M 11.21M
Adjusted Diluted Earnings per Share		 ($21.72) ($30.84) ($28.92) ($47.76) ($44.64) ($21.00) ($36.00) ($23.04) ($13.38) ($6.69) ($0.55)
Adjusted Weighted Average Diluted Shares Outstanding		 1.44M 1.44M 1.69M 2.13M 2.72M 3.19M 4.01M 4.03M 4.58M 6.00M 11.21M
Adjusted Basic & Diluted Earnings per Share		 ($21.72) ($30.84) ($28.92) ($47.76) ($44.64) ($21.00) ($36.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.31M 1.44M 1.48M 1.90M 2.19M 2.95M 3.61M 4.33M 5.48M 7.50M 15.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -32 -37 -65 -72 -45 -64 -66 -45 -32 -8.48
Normalized NOPAT Margin		 0.00% 0.00% -405.35% -438.49% -450.41% -57.32% -1,019.11% 0.00% -631.75% -111.48% -11.73%
Pre Tax Income Margin		 0.00% 0.00% -575.00% -605.59% -616.48% -78.57% -2,116.82% 0.00% -854.32% -139.72% -8.47%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Assembly Biosciences

This table displays calculated financial ratios and metrics derived from Assembly Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 52,614,194.00 65,709,112.00 5,482,752.00 5,513,308.00 6,345,561.00 6,356,286.00 7,503,385.00 7,637,553.00 7,672,261.00 15,817,140.00 15,862,705.00
DEI Adjusted Shares Outstanding		 4,384,516.00 5,475,759.00 5,482,752.00 5,513,308.00 6,345,561.00 6,356,286.00 7,503,385.00 7,637,553.00 7,672,261.00 15,817,140.00 15,862,705.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.29 -2.00 -1.66 -2.02 -1.51 -1.63 -1.18 -1.34 -1.20 1.40 -0.57
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 2.71% 62.82% 12.81% 57.62% 477.26% -12.80%
EBITDA Growth		 34.42% 45.64% 38.62% 25.10% 22.83% 3.00% 12.92% 12.88% 7.76% 263.99% -16.48%
EBIT Growth		 35.70% 45.38% 45.15% 30.22% 27.19% 8.12% 7.34% 9.10% 0.67% 271.69% -14.37%
NOPAT Growth		 35.70% 45.38% 45.15% 30.22% 27.19% 8.12% 7.34% 9.10% 0.67% 345.27% -14.37%
Net Income Growth		 37.70% 51.05% 52.10% 34.00% 33.34% 5.72% 2.85% 8.55% 4.34% 313.74% -2.96%
EPS Growth		 37.70% 51.05% 62.78% 48.97% 54.10% 28.03% 29.52% 32.83% 52.32% 214.53% 53.85%
Operating Cash Flow Growth		 30.14% 482.50% 21.62% -25.49% -10.08% -100.55% -27.64% 2.01% 0.73% 3,598.03% 5.73%
Free Cash Flow Firm Growth		 -150.29% 657.58% 757.36% 805.24% 562.25% -125.91% -133.40% -141.60% -147.03% 5.06% -87.14%
Invested Capital Growth		 28.03% -896.53% -2,895.71% -1,426.77% -1,433.61% 11.70% 20.50% 23.69% 27.68% 47.47% 56.19%
Revenue Q/Q Growth		 0.00% 0.00% -19.24% 47.50% -19.78% 7.48% 28.03% 2.20% 12.08% 293.63% -80.66%
EBITDA Q/Q Growth		 13.04% 18.22% 4.06% -9.78% 10.41% -2.80% 13.87% -9.83% 5.15% 282.76% -161.18%
EBIT Q/Q Growth		 13.95% 16.59% 14.52% -13.74% 10.22% -5.26% 13.80% -11.59% 1.89% 281.93% -157.43%
NOPAT Q/Q Growth		 13.95% 16.59% 14.52% -13.74% 10.22% -5.26% 13.80% -11.59% 1.89% 359.89% -140.20%
Net Income Q/Q Growth		 14.65% 23.98% 17.20% -22.86% 13.80% -7.51% 14.68% -15.65% 9.83% 340.21% -141.10%
EPS Q/Q Growth		 14.65% 23.98% 30.54% -19.28% 23.74% -13.91% 31.98% -13.68% 45.86% 373.61% -127.41%
Operating Cash Flow Q/Q Growth		 -1.61% 631.82% -124.94% 6.87% 10.86% 97.33% -5,658.97% 28.50% 9.70% 194.08% -255.21%
Free Cash Flow Firm Q/Q Growth		 -41.76% 681.36% -1.73% -12.92% -7.08% -132.58% -26.68% -8.46% -5.05% 34.23% -149.70%
Invested Capital Q/Q Growth		 7.91% -1,882.87% 9.84% 7.26% 7.49% -14.17% 18.83% 10.98% 12.34% 17.06% 32.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -174.05% -206.76% -153.88% -171.86% -164.37% -110.59% -118.84% -100.57% 46.70% -147.73%
Operating Margin		 0.00% -175.22% -185.46% -143.01% -160.06% -156.75% -105.54% -115.24% -100.87% 46.62% -138.44%
EBIT Margin		 0.00% -175.22% -185.46% -143.01% -160.06% -156.75% -105.54% -115.24% -100.87% 46.62% -138.44%
Profit (Net Income) Margin		 0.00% -153.04% -156.91% -130.69% -140.44% -140.48% -93.62% -105.94% -85.24% 52.01% -110.54%
Tax Burden Percent		 100.00% 100.30% 100.00% 103.78% 100.00% 99.27% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.83% 87.08% 84.60% 88.06% 87.74% 90.28% 88.70% 91.93% 84.50% 111.57% 79.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -100.84% -98.95% -99.78% -101.78% -120.51% -107.92% -133.65% -147.64% -36.94% -5.10% -5.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -10.52% -23.66% -33.78% -59.70% -34.93% -31.01% -39.08% -22.05% 17.89% -58.85%
Return on Assets (ROA)		 0.00% -9.19% -20.02% -30.87% -52.38% -31.30% -27.50% -35.92% -18.63% 19.96% -46.99%
Return on Common Equity (ROCE)		 -100.84% -98.95% -99.78% -101.78% -120.51% -107.92% -133.65% -147.64% -36.94% -5.10% -5.66%
Return on Equity Simple (ROE_SIMPLE)		 -174.19% 0.00% -157.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -8.79 -7.51 -8.54 -7.67 -8.07 -6.96 -7.77 -7.62 20 -7.96
NOPAT Margin		 0.00% -122.65% -129.82% -100.11% -112.04% -109.72% -73.88% -80.67% -70.61% 46.62% -96.91%
Net Nonoperating Expense Percent (NNEP)		 -5.02% -1.96% -1.68% -3.09% -2.75% -1.87% -1.82% -2.64% -0.96% 1.27% -0.71%
Return On Investment Capital (ROIC_SIMPLE)		 - -21.38% -23.04% -24.63% -29.49% -24.20% -25.65% -42.90% -4.17% 9.58% -4.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 121.57% 80.12% 52.47% 62.62% 62.65% 47.87% 47.72% 47.13% 12.76% 57.02%
R&D to Revenue		 0.00% 153.65% 205.34% 190.54% 197.44% 194.10% 157.67% 167.52% 153.74% 40.62% 181.42%
Operating Expenses to Revenue		 0.00% 275.22% 285.46% 243.01% 260.06% 256.75% 205.54% 215.24% 200.87% 53.38% 238.44%
Earnings before Interest and Taxes (EBIT)		 -15 -13 -11 -12 -11 -12 -9.94 -11 -11 20 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -12 -12 -13 -12 -12 -10 -11 -11 20 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.12 1.31 2.24 2.18 3.69 3.01 2.64 7.65 1.08 2.60 2.22
Price to Tangible Book Value (P/TBV)		 1.12 1.31 2.24 2.18 3.69 3.01 2.64 7.65 1.08 2.60 2.22
Price to Revenue (P/Rev)		 0.00 7.52 5.63 3.52 3.39 3.52 2.23 4.16 5.28 7.44 6.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.04 0.00 0.00 1.91 0.00 4.01 3.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.79 -1.81 -1.89 -2.08 -3.25 -3.42 -3.49 -1.57 -1.50 -1.41
Leverage Ratio		 1.20 1.93 1.97 2.03 2.24 3.44 3.66 3.72 1.63 1.57 1.48
Compound Leverage Factor		 1.15 1.68 1.67 1.79 1.97 3.10 3.25 3.42 1.38 1.75 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -18.16 -7.12 -8.18 -8.64 -10.01 -8.40 -10.62 -12.91 -2.00 3.32 3.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.96 3.41 3.02 2.74 2.36 2.42 2.05 1.64 4.44 5.22 6.65
Quick Ratio		 6.48 3.32 2.92 2.65 2.28 2.34 1.95 1.59 4.37 5.11 6.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 71 70 61 57 -19 -23 -25 -27 -18 -44
Operating Cash Flow to CapEx		 -10,182.35% 103,728.17% -131,171.43% -122,157.14% 0.00% 0.00% 0.00% 0.00% -36,030.95% 59,320.83% -116,300.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.06 0.13 0.24 0.37 0.22 0.29 0.34 0.22 0.38 0.43
Accounts Receivable Turnover		 0.00 14.51 34.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 12.70 26.26 48.27 64.60 85.26 104.06 117.07 136.48 286.35 305.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 25.15 10.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 25.15 10.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.50 -89 -80 -75 -69 -79 -64 -57 -50 -41 -28
Invested Capital Turnover		 0.00 -0.15 -0.31 -0.54 -0.77 -0.34 -0.45 -0.51 -0.63 -1.20 -1.55
Increase / (Decrease) in Invested Capital		 1.75 -80 -78 -70 -64 10 16 18 19 37 36
Enterprise Value (EV)		 0.35 -76 -40 -34 1.12 -12 -19 63 -36 290 214
Market Capitalization		 47 54 73 76 96 100 72 138 196 538 440
Book Value per Share		 $0.79 $0.63 $5.95 $6.29 $4.10 $5.25 $3.62 $2.37 $23.81 $13.07 $12.52
Tangible Book Value per Share		 $0.79 $0.63 $5.95 $6.29 $4.10 $5.25 $3.62 $2.37 $23.81 $13.07 $12.52
Total Capital		 42 41 33 35 26 33 27 18 183 207 199
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -46 -130 -113 -109 -95 -112 -91 -75 -233 -248 -227
Capital Expenditures (CapEx)		 0.14 0.07 0.01 0.01 0.00 0.00 0.00 0.00 0.04 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.67 -36 -35 -38 -38 -44 -42 -45 -49 -42 -29
Debt-free Net Working Capital (DFNWC)		 43 95 78 72 57 68 49 30 183 206 198
Net Working Capital (NWC)		 43 95 78 72 57 68 49 30 183 206 198
Net Nonoperating Expense (NNE)		 3.89 2.18 1.57 2.61 1.94 2.26 1.86 2.43 1.58 -2.29 1.12
Net Nonoperating Obligations (NNO)		 -46 -130 -113 -109 -95 -112 -91 -75 -233 -248 -227
Total Depreciation and Amortization (D&A)		 -0.20 0.08 -1.23 -0.93 -0.81 -0.56 -0.48 -0.35 0.03 0.03 -0.76
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -498.19% -266.92% -174.86% -135.48% -155.61% -131.03% -134.76% -132.09% -58.56% -40.77%
Debt-free Net Working Capital to Revenue		 0.00% 1,320.15% 605.61% 333.58% 199.74% 237.38% 152.07% 90.76% 493.22% 284.59% 277.95%
Net Working Capital to Revenue		 0.00% 1,320.15% 605.61% 333.58% 199.74% 237.38% 152.07% 90.76% 493.22% 284.59% 277.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.24) ($28.68) ($1.66) ($1.98) ($1.51) ($1.72) ($1.17) ($1.33) ($0.72) $1.97 ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 4.38M 381.45K 5.48M 5.64M 6.35M 6.00M 7.51M 7.66M 12.69M 11.21M 16.90M
Adjusted Diluted Earnings per Share		 ($3.24) ($28.68) ($1.66) ($1.98) ($1.51) ($1.72) ($1.17) ($1.33) ($0.72) $1.97 ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 4.38M 381.45K 5.48M 5.64M 6.35M 6.00M 7.51M 7.66M 12.69M 11.21M 16.90M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($28.68) $0.00 $0.00 $0.00 ($1.72) $0.00 $0.00 $0.00 $1.97 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.48M 456.90K 5.51M 6.35M 6.36M 7.50M 7.64M 7.67M 15.82M 15.86M 15.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -8.79 -7.51 -8.54 -7.67 -8.07 -6.96 -7.77 -7.62 14 -7.96
Normalized NOPAT Margin		 0.00% -122.65% -129.82% -100.11% -112.04% -109.72% -73.88% -80.67% -70.61% 32.63% -96.91%
Pre Tax Income Margin		 0.00% -152.58% -156.91% -125.93% -140.44% -141.51% -93.62% -105.94% -85.24% 52.01% -110.54%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Assembly Biosciences showed a much stronger balance sheet at the end of Q1 2026 than it did a year earlier, but operating performance remains volatile and the company is still burning cash.

  • Cash, cash equivalents, and short-term investments totaled about $226.6 million in Q1 2026, giving the company substantial liquidity.
  • Total assets rose sharply to $235.5 million from $99.0 million in Q1 2025, largely reflecting a much larger cash/investment position and equity financing activity.
  • The company ended Q1 2026 with common equity of $198.6 million, well above the prior-year level.
  • Revenue in Q1 2026 was $8.2 million, up from $5.8 million in Q1 2024, showing some top-line growth over the longer comparison period.
  • Interest and investment income was $2.3 million in Q1 2026, helping offset operating losses.
  • The company’s deferred revenue balance remains meaningful, with $29.1 million in current deferred revenue and $1.9 million in noncurrent operating liabilities, which may support future recognized revenue.
  • Share count has increased materially over the past year, which suggests dilution has been used as a financing tool.
  • Operating expenses remain heavily weighted toward research and development, which is typical for a biotech company but also keeps near-term profitability under pressure.
  • Q1 2026 posted a net loss of $9.1 million, compared with net income of $22.1 million in Q4 2025, highlighting a sharp quarter-to-quarter swing.
  • Operating cash flow was negative at $(22.1) million in Q1 2026, versus positive $14.2 million in Q4 2025.
  • Investing cash flow was also negative at $(5.4) million in Q1 2026 as the company continued to move capital in and out of investments.
  • Despite the large cash balance, the business remains unprofitable on an operating basis, with operating loss of $11.4 million in Q1 2026.
  • Retained earnings were still deeply negative at $(841.1) million, reflecting the long history of accumulated losses.

Overall, Assembly Biosciences looks well-funded in the near term, but investors should watch whether the company can turn its growing revenue base into sustainable operating leverage. For now, the main story is strong liquidity paired with ongoing losses and dilution risk.

07/28/26 07:59 AM ETAI Generated. May Contain Errors.

Assembly Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Assembly Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, Assembly Biosciences' net income changed from -$28.45 million in 2015 to -$6.12 million in 2025, a change of -78.5%. Find out what analysts predict for Assembly Biosciences in the coming months.

Assembly Biosciences' total operating income in 2025 was -$12.12 million, based on the following breakdown:
  • Total Gross Profit: $72.30 million
  • Total Operating Expenses: $84.42 million

Over the last 10 years, Assembly Biosciences' total revenue changed from $0.00 in 2015 to $72.30 million in 2025, a change of 7,230,300,000.0%.

Assembly Biosciences' total liabilities were at $50.84 million at the end of 2025, a 40.8% decrease from 2024, and a 238.9% increase since 2015.

In the past 10 years, Assembly Biosciences' cash and equivalents has ranged from $19.84 million in 2023 to $82.03 million in 2017, and is currently $58.45 million as of their latest financial filing in 2025.

Over the last 10 years, Assembly Biosciences' book value per share changed from 6.89 in 2015 to 13.07 in 2025, a change of 89.6%.


Related Companies

Financial statements for NASDAQ:ASMB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
A 50-year dollar arrangement just ended - what it means for you
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...
Golden Portfolio | Sponsoredtc pixel
What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
A storm is coming
The U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...
Stansberry Research | Sponsoredtc pixel